BR9807332A - Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose - Google Patents

Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose

Info

Publication number
BR9807332A
BR9807332A BR9807332-0A BR9807332A BR9807332A BR 9807332 A BR9807332 A BR 9807332A BR 9807332 A BR9807332 A BR 9807332A BR 9807332 A BR9807332 A BR 9807332A
Authority
BR
Brazil
Prior art keywords
leishmaniasis
therapy
diagnosis
leishmania antigens
polypeptides
Prior art date
Application number
BR9807332-0A
Other languages
English (en)
Inventor
Steven G Reed
Antonio Campos-Neto
John R Webb
Davin C Dillon
Yasir A Skeiky
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/798,841 external-priority patent/US6709661B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BR9807332A publication Critical patent/BR9807332A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTìGENOS DE LEISHMANIA PARA UTILIZAçãO NA TERAPIA E DIAGNóSTICO DE LEISHMANIOSE" São revelados composições e processos para prevenir, tratar e detectar leishmaniose e estimular respostas imunes em pacientes. Os compostos providos incluem polipeptídeos que contém, pelo menos, uma porção imunogênica de um ou mais antígenos de Leishmania, ou uma variante dos mesmos. Vacinas e composições farmacêuticas compreendendo tais polipeptídeos, ou moléculas de DNA codificando tais polipeptídeos são também providas e podem ser usadas, por exemplo, na prevenção e terapia de leishmaniose, bem como para detecção de infecção por Leishmania.
BR9807332-0A 1997-02-12 1998-02-12 Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose BR9807332A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/798,841 US6709661B1 (en) 1995-09-22 1997-02-12 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US92060997A 1997-08-27 1997-08-27
PCT/US1998/003002 WO1998035045A2 (en) 1997-02-12 1998-02-12 Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Publications (1)

Publication Number Publication Date
BR9807332A true BR9807332A (pt) 2000-10-31

Family

ID=27122041

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807332-0A BR9807332A (pt) 1997-02-12 1998-02-12 Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose

Country Status (3)

Country Link
EP (2) EP2284186A1 (pt)
BR (1) BR9807332A (pt)
WO (1) WO1998035045A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6673351B1 (en) * 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
CA2463581A1 (en) * 2001-10-12 2003-04-24 U.S. Army Medical Research And Materiel Command Microfluidized leishmania antigen and methods of making and using thereof
EP2291394B1 (en) 2008-07-03 2017-03-15 Infectious Disease Research Institute Fusion proteins and their use in the diagnosis and treatment of leishmaniasis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
PT804581E (pt) * 1994-04-22 2002-02-28 Corixa Corp Compostos e metodos para a estimulacao e reforco das respostas imunitarias protectoras e da producao de il-12
US5912166A (en) * 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis

Also Published As

Publication number Publication date
WO1998035045A2 (en) 1998-08-13
EP0981624A2 (en) 2000-03-01
WO1998035045A3 (en) 1998-10-29
EP2284186A1 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
PT82457B (pt) Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
CS553490A3 (en) Transdermal therapeutic system
BR9809445A (pt) Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico.
PT88138A (pt) Processo para a producao de uma forma de administracao ou de dosagem para substancias medicinais activas por meio de um processo de impressao
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
SE8602530D0 (sv) Nasal pharmaceutical compositions
BR9807332A (pt) Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
DE69812100T2 (de) Adenosin enthaltendes arzneimittel
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
FI893681A (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
BR0316053A (pt) Uso de um polipeptìdeo de choque térmico e/ou uma sequência de ácido nucléico codificadora, e, método de aliviar a dor
BR9910594A (pt) Vìrus de herpes simplex, uso de um vìrus de herpessimplex, composição farmacêutica e processospara estudar a função de um gene heterólogo emuma célula de mamìfero, para produzir um vìrus deherpes simplex e para tratar um distúrbio ou uma lesãodo sistema nervoso de um mamìfero
WO2002098359A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP1422238A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
NO920524D0 (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse
DE3877747D1 (de) Glasartige matrize zur verabreichung von heilmitteln.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE3687448D1 (de) Verwendung von 6h-7,8-dihydrothiapyrano(3,2d)pyrimidinen zur herstellung von arzneimitteln zur verwendung als hypoglykaemische mittel oder als abmagerungsmittel fuer fettsuechtige patienten.
NL300254I2 (nl) Verzwakte herpesvirussen, herpesvirussen die vreemd DNA omvatten dat codeert voor een aminozuursequentie en vaccin dat het bevat
DK98788A (da) Benzylaminoaryl-dihydropyridinlactoner, fremgangmsaade til deres fremstilling samt deres anvendelse som laegemidler

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2448 DE 05-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.